



Daiichi-Sankyo

Stock code
number 4568

Reference Data

(Consolidated Financial Results for 1Q FY2008)

[1] Summary of Income Statement	P1
[2] Currency Rate	P1
[3] Sales of Global Products	P2
[4] Overseas Sales	P2
[5] Consolidated Segment Information – Operating Segment	P3
[6] Consolidated Segment Information – Geographic Segment	P3
[7] Status of Major Companies	P4
[8] Number of Employees	P7
[9] R&D Pipeline	P8
<Historical Data>	P10

July 31, 2008

Corporate Communications Department
<http://www.daiichisankyo.com>

(This page is intentionally left blank)

1. Summary of Income Statement

(Billion of yen)

	FY2008 Results				Details FY07 1Q Results ==> FY08 1Q Results	FY2008 Forecast			
	1Q	Progress	YoY Changes			1st half	Full Year		
Net sales	<-13.5> 100.0	203.7	50.9%	-31.8	Non-pharmaceutical business: -8.1 Change in fiscal year-end: -14.1	<-9.9> 100.0	400.0	<-4.6> 100.0	840.0
Cost of sales	23.9	48.6	48.4%	-9.2		25.1	100.5	24.8	208.5
Selling, general and administrative expenses	56.5	115.1	46.1%	5.2	Non-pharmaceutical business: -1.2 Change in fiscal year-end: -8.6	62.4	249.5	59.7	501.5
Research and development expenses	18.1	36.9	43.4%	4.2		21.3	85.0	20.1	169.0
Other expenses	38.4	78.2	47.5%	1.1		41.1	164.5	39.6	332.5
Operating income	<-41.0> 19.6	40.0	80.0%	-27.8	Non-pharmaceutical business: +0.2 Change in fiscal year-end: -1.9	<-46.8> 12.5	50.0	<-17.1> 15.5	130.0
Non-operating income		3.6		-2.2			6.0		11.0
Non-operating expenses		2.8		0.7			2.0		3.0
Ordinary income	<-43.0> 20.1	40.9	75.7%	-30.8		<-46.4> 13.5	54.0	<-18.4> 16.4	138.0
Extraordinary gains		0.0		-3.9			2.5		3.0
Extraordinary losses		1.3		-2.7			3.0		5.5
Income before income taxes and minority interests	19.4	39.5		-32.0		13.4	53.5	16.1	135.5
Net income	<-39.4> 12.3	25.1	83.6%	-16.3		<-50.2> 7.5	30.0	<-18.1> 9.5	80.0

<Performance excluding the effects of changes in fiscal year-end and non-pharmaceutical business>

(Billion of yen)

	FY2008 Results				Details FY07 1Q Results ==> FY08 1Q Results	FY2008 Forecast			
	1Q	Progress	YoY Changes			1st half	Full Year		
Net sales	<-4.5> 100.0	203.7	50.9%	-9.6	Commercial rights transfer (Coversyl, Zantac, etc): -4.3 Loss from currency fluctuation: approximately -9.0 NHI drug price revision: approximately -8.0 Azor (lump sum payment received): +4.7	<-3.2> 100.0	400.0	<0.7> 100.0	840.0
Cost of sales	23.9	48.6	48.4%	1.5	+1.8 pt: Change in business scheme of Panalidine, etc.	25.1	100.5	24.8	208.5
Selling, general and administrative expenses	56.5	115.1	46.1%	15.1		62.4	249.5	59.7	501.5
Research and development expenses	18.1	36.9	43.4%	4.7	Increase in development costs such as Denosumab	21.3	85.0	20.1	169.0
Other expenses	38.4	78.2	47.5%	10.3	Increase in personnel cost (Japan): +2.1 (temporarily decreased in FY07 due to the integration of retirement benefit and pension plans) Intensive investment in U.S./EU: +7.1 (approximately 600 increase in number of MRS)	41.1	164.5	39.6	332.5
Operating income	<-39.5> 19.6	40.0	80.0%	-26.1		<-46.1> 12.5	50.0	<-16.2> 15.5	130.0
Non-operating income		3.6		-2.0			6.0		11.0
Non-operating expenses		2.8		0.7			2.0		3.0
Ordinary income	<-41.4> 20.1	40.9	75.7%	-28.9		<-45.6> 13.5	54.0	<-17.4> 16.4	138.0
Extraordinary gains		0.0		-2.2	Sales of property, plant and equipment: -1.3		2.5		3.0
Extraordinary losses		1.3		-2.7	Loss on business integration/restructuring: -2.6		3.0		5.5
Income before income taxes and minority interests	19.4	39.5		-28.4		13.4	53.5	16.1	135.5
Net income	<-34.2> 12.3	25.1	83.6%	-13.0		<-47.6> 7.5	30.0	<-15.9> 9.5	80.0

<Notes>

Non-pharmaceutical business were fully spun off by the end of FY2007.
FY2007 1Q results for Daiichi Sankyo Europe GmbH (DSE) was 6 months due to change in its fiscal year-end.

2. Currency Rate

	FY2007 Results	FY2008 Results	FY2008 Forecast		FY2008 Forecast	
	1Q	1Q	1st Half	Full Year	Impact of one yen per USD/EUR change in currency rate	
JPY / USD (average)	120.8	104.6	100.0	100.0	Net Sales	¥2.1 billion
JPY / EUR (average)	159.6	163.4	155.0	155.0	Operating Income	¥0.3 billion
					Net Sales	¥0.5 billion
					Operating Income	-

3. Sales of Global Products

					(Billion of yen)					
	FY2008 Results				FY2008 Forecast		YoY changes excluding fiscal year-end changes			
	1Q	Progress	YoY Changes	1st half	Full Year	1Q	1st half			
Olmesartan <antihypertensive> (area)	<-4.5>	50.7	50.7%	-2.4	<-3.5>	100.0	214.0	<-8.6>	4.0	9.8
Olmetec JPN	<12.8>	15.6	47.3%	1.8	<25.0>	33.0	68.0			
Benicar / Benicar HCT US	<2.6>	23.4	57.0%	0.6	<-7.8>	41.0	84.0			
AZOR US	<->	1.4	45.7%	1.4	<->	3.0	8.5			
Olmetec / Olmetec Plus * EU	<-44.3>	8.3	43.7%	-6.6	<-14.7>	19.0	42.0	<-2.6>		<19.6>
Export / Asian & LA subsidiaries, etc	<30.4>	2.0	50.8%	0.5	<14.2>	4.0	11.5			
Levofloxacin <synthetic antibacterial> (area)	<-13.0>	25.8	51.5%	-3.7	<-5.5>	50.0	104.0			
Cravit JPN	<-15.5>	10.2	46.4%	-1.9	<-0.4>	22.0	47.0			
Export, etc	<-11.3>	9.6	59.7%	-1.2	<-9.6>	16.0	32.0			
Royalty	<-12.6>	4.1	50.9%	-0.6	<-13.7>	8.0	17.0			
Asian subsidiaries	<-1.8>	1.9	48.1%	0.0	<3.0>	4.0	8.0			
Pravastatin <antihyperlipidemic> (area)	<-25.8>	16.1	48.7%	-5.6	<-18.1>	33.0	62.5	<-19.9>	-4.0	<-14.7>
Mevalotin JPN	<-17.1>	13.5	48.4%	-2.8	<-11.6>	28.0	53.0			
Export	<-39.0>	1.0	104.9%	-0.7	<-65.4>	1.0	2.0			
European subsidiaries *	<-74.3>	0.7	29.2%	-2.1	<-39.4>	2.5	4.5	<-41.0>	-0.5	<-1.0>
Asian & Latin American subsidiaries	<-3.1>	0.8	50.8%	0.0	<-6.6>	1.5	3.0			

* The accounting period of Daiichi Sankyo Europe GmbH (DSE) was 15 months from January 2007 to March 2008, following a change in its fiscal year-end from December to March. Three months results of Olmetec / Olmetec Plus and Pravastatin from Jan-07 to Mar-07 were ¥6.4 billion (€40 million) and ¥1.6 billion (€10 million), respectively.

4. Overseas Sales

					(Billion of yen)					
	FY2008 Results				FY2008 Forecast		YoY changes excluding fiscal year-end changes			
	1Q	Progress	YoY Changes	1st half	Full Year	1Q	1st half			
Overseas sales	<-15.9>	88.7	55.8%	-16.8	<-15.6>	159.0	336.0	<-2.9>	-2.7	-15.4
Overseas sales ratio		43.5%				39.8%	40.0%			
North America	<3.9>	58.3	60.7%	2.2	<-13.7>	96.0	204.0			
Europe *	<-42.6>	22.4	48.8%	-16.7	<-18.9>	46.0	96.0	<-10.1>	-2.5	<8.0>
Asia / Latin America, etc	<-22.3>	8.0	46.9%	-2.3	<-17.3>	17.0	36.0			

* The accounting period of Daiichi Sankyo Europe GmbH (DSE) was 15 months from January 2007 to March 2008, following a change in its fiscal year-end from December to March. The net sales of DSE for the period from January to March 2007 was ¥14.1 billion.

5. Consolidated Segment information - Operating Segment

(Billion of yen)

	FY2007 Results			FY2008 Results	
	1Q	1st half	Full Year	1Q	YoY Changes
Net Sales	<-12.9> 235.5	<-8.7> 443.7	<-5.3> 880.1	<-13.5> 203.7	-31.8
Pharmaceuticals	<-8.8> 225.8	<-3.9> 424.0	<0.4> 840.8	<-10.2> 202.9	-23.0
Domestic	<-3.9> 112.5	<-0.3> 214.5	<0.9> 437.3	<-8.2> 103.3	-9.2
Overseas *	<-6.5> 103.2	<-0.3> 184.7	<4.3> 352.5	<-14.1> 88.7	-14.5
OTC drugs	<-11.5> 9.9	<-0.6> 24.4	<4.9> 50.3	<3.1> 10.2	0.3
Other	<-57.9> 9.7	<-55.7> 19.7	<-57.4> 39.3	<-91.5> 0.8	-8.9
Operating income	<-11.6> 67.8	<-19.9> 93.9	<-15.0> 156.8	<-41.0> 40.0	-27.8
Pharmaceuticals	<15.1> 68.3	<24.1> 94.2	<18.5> 155.6	<-42.3> 39.4	-28.9
Other	<-> -0.3	<-> -0.4	<-> 1.0	<-> 0.5	0.9

* The accounting period of Daiichi Sankyo Europe GmbH (DSE) was 15 months from January 2007 to March 2008, following a change in its fiscal year-end from December to March. The operating results of DSE for the period from January to March 2007 was net sales of ¥14.1 billion and operating income of ¥1.8 billion.

6. Consolidated Segment information - Geographic Segment

(Billion of yen)

	FY2007 Results			FY2008 Results	
	1Q	1st half	Full Year	1Q	YoY Changes
Net Sales	<-12.9> 100.0 235.5	<-8.7> 100.0 443.7	<-5.3> 100.0 880.1	<-13.5> 100.0 203.7	-31.8
Japan	<-15.3> 64.5 151.8	<-13.6> 66.6 295.4	<-10.4> 68.0 598.1	<-12.6> 65.1 132.7	-19.2
North America	<-36.6> 19.1 45.0	<-17.4> 20.2 89.7	<-7.1> 20.2 178.0	<12.5> 24.9 50.7	5.6
Europe*	<98.3> 13.7 32.3	<66.0> 10.2 45.3	<46.1> 8.9 78.0	<-53.1> 7.4 15.2	-17.2
Asia / Latin America, etc	<59.1> 2.7 6.3	<66.5> 3.0 13.3	<55.0> 3.0 26.1	<-16.9> 2.6 5.2	-1.1
Operating income	<-11.6> 67.8	<-19.9> 93.9	<-15.0> 156.8	<-41.0> 40.0	-27.8
Japan	47.4	69.4	107.1	18.5	
North America	13.2	22.5	37.6	16.9	
Europe *	4.4	3.4	10.7	1.2	
Asia / Latin America, etc	0.7	1.3	2.5	0.7	

* The accounting period of Daiichi Sankyo Europe GmbH (DSE) was 15 months from January 2007 to March 2008, following a change in its fiscal year-end from December to March. The operating results of DSE for the period from January to March 2007 was net sales of ¥14.1 billion and operating income of ¥1.8 billion.

7. Status of Major Companies

7-1. Daiichi Sankyo Co., Ltd.

	FY2008 Results			FY2008 Forecast	
	1Q	Progress	YoY Changes	1st half	Full Year
Total net sales of ethical pharmaceuticals	<-8.8> 100.9	50.5%	-9.8	<-5.2> 200.0	<-1.7> 420.0
Cardiovascular disease	<-5.9> 60.0	49.2%	-3.8	<-0.2> 122.0	<1.0> 245.0
Olmotec <antihypertensive>	<12.8> 15.6	47.3%	1.8	<25.0> 33.0	<23.2> 68.0
Calblock <antihypertensive>	<19.4> 3.0	43.1%	0.5	<44.4> 7.0	<37.1> 14.0
Artist <antihypertensive>	<3.3> 5.7	51.6%	0.2	<4.2> 11.0	<4.1> 22.0
Mevalotin <antihyperlipidemic agent>	<-17.1> 13.5	48.4%	-2.8	<-11.6> 28.0	<-13.9> 53.0
Kremezin <treatment for chronic renal failure>	<3.9> 3.2	53.0%	0.1	<-2.6> 6.0	<13.0> 14.0
Hanp <treatment for acute cardiac failure>	<-7.8> 2.4	48.0%	-0.2	<11.0> 5.0	<2.3> 10.0
Livalo <antihyperlipidemic agent>	<10.0> 1.5	49.5%	0.1	<14.1> 3.0	<46.6> 8.0
Sunrhythm <antiarrhythmic agent>	<-4.2> 3.1	44.0%	-0.1	<13.6> 7.0	<-0.7> 12.0
Fastic <antidiabetic agent>	<-0.5> 1.3	44.3%	0.0	<14.4> 3.0	<15.8> 6.0
Infectious diseases / bone and joint diseases / immunological allergic diseases / urology	<-8.3> 30.8	48.1%	-2.8	<-0.4> 64.0	<-1.4> 136.0
Cravit <synthetic antibacterial agent>	<-15.5> 10.2	46.4%	-1.9	<-0.4> 22.0	<-0.8> 47.0
Loxonin <anti-inflammatory analgesic>	<2.2> 8.4	44.4%	0.2	<15.9> 19.0	<16.0> 39.0
Mobic <anti-inflammatory analgesic>	<-13.1> 2.4	40.8%	-0.4	<11.4> 6.0	<7.3> 11.0
Urief <treatment for dysuria>	<59.7> 1.8	44.0%	0.7	<72.0> 4.0	<66.2> 9.0
Zyrtec <antiallergic agent>	<-23.8> 2.0	50.7%	-0.6	<-11.5> 4.0	<-16.9> 9.0
Contrast agents / cancer / gastric diseases	<-22.2> 12.3	47.1%	-3.5	<-14.1> 26.0	<-11.3> 52.0
Omnipaque <contrast agent>	<-11.3> 7.3	52.1%	-0.9	<-12.0> 14.0	<-10.1> 28.0
Topotecin <anticancer agent>	<0.7> 1.6	53.9%	0.0	<-3.3> 3.0	<-2.8> 6.0

(Billion of yen)

7-2. Daiichi Sankyo Healthcare Co., Ltd

	FY2008 Results				(Billion of yen)		
	1Q	Progress	YoY Changes		FY2008 Forecast		
					1st half	Full Year	
Daiichi Sankyo Healthcare Co., Ltd	<3.1>	10.2	39.4%	0.3	<6.4>	<7.3>	
					26.0	54.0	
LuLu Series	<8.7>	1.2	25.0%	0.1	<3.5>	<3.2>	10.3
Gaster 10	<-15.5>	0.7	42.7%	-0.1	<0.3>	<9.1>	3.8
Shin-Sankyo Ichoyaku series	<7.9>	0.7	43.1%	0.1	<20.1>	<0.8>	3.5
Patecs series	<-19.5>	0.8	52.3%	-0.2	<-18.4>	<0.1>	3.0
Transino	<->	0.7	33.9%	0.7	<40.1>	<91.5>	5.0

7-3. Daiichi Sankyo, Inc. (US)

	FY2008 Results				(Billion of yen)		
	1Q	Progress	YoY Changes		FY2008 Forecast		
					1st half	Full Year	
Daiichi Sankyo, Inc. (DSI)	<12.0>	37.2	63.0%	3.9	<-9.4>	<1.7>	
mil USD	<29.4>	356	60.3%	80	<8.1>	<16.2>	129.0
Benicar / Benicar HCT <antihypertensive>	<2.6>	23.4	57.0%	0.6	<-7.8>	<-4.4>	84.0
mil USD	<18.6>	223	54.5%	35	<10.0>	<9.2>	840
Azor <antihypertensive>	<->	1.4	45.7%	1.4	<->	<233.7>	8.5
mil USD	<->	13	43.7%	13	<->	<281.3>	85
Welchol <antihyperlipidemic / type 2 diabetes>	<11.0>	6.4	56.0%	0.7	<0.9>	<10.0>	25.0
mil USD	<28.2>	62	53.8%	14	<20.4>	<25.7>	250

7-4. Luitpold Pharmaceuticals, Inc. (US)

	FY2008 Results				(Billion of yen)		
	1Q	Progress	YoY Changes		FY2008 Forecast		
					1st half	Full Year	
Luitpold Pharmaceuticals, Inc. (LPI)	<13.8>	13.5	67.5%	1.6	<-18.7>	<-21.7>	
mil USD	<31.4>	129	64.6%	31	<-3.0>	<-10.5>	400
Venofer <treatment for iron deficiency anemia>	<23.1>	8.3	72.5%	1.6	<-22.1>	<-26.0>	23.0
mil USD	<42.2>	80	69.3%	24	<-7.1>	<-15.4>	230

7-5. Daiichi Sankyo Europe GmbH

	FY2008 Results				(Billion of yen)			YoY changes excluding fiscal year-end changes		
					FY2008 Forecast					
	1Q	Progress	YoY Changes		1st half	Full Year	1Q	1st half		
Daiichi Sankyo Europe GmbH (DSE)	<-53.1>	15.2	41.0%	-17.3	<-18.3>	<1.3>	<-16.6>	<-18.7>	5.8	
mil €	<-54.2>	93	38.7%	-111	<-15.1>	<5.0>	<-18.6>	<23.7>	46	
Olmetec / Olmetec Plus <antihypertensive>	<-44.3>	8.3	43.7%	-6.6	<-14.7>	<0.4>	<-2.6>	<19.6>	3.1	
mil €	<-45.6>	51	40.7%	-43	<-10.0>	<3.6>	<-4.9>	<26.4>	26	
Mevalotin <antihyperlipidemic agent>	<-74.3>	0.7	29.2%	-2.1	<-39.4>	<-32.7>	<-41.0>	<-42.3>	0.0	
mil €	<-74.9>	4	27.9%	-13	<-37.8>	<-28.0>	<-1.0>	<1.9>	0	
Evista <treatment for osteoporosis>	<71.7>	3.2	43.3%	1.4	<191.8>	<186.0>	<253.5>	<369.7>	5.9	
mil €	<67.7>	20	41.4%	8	<199.5>	<193.8>	<245.2>	<383.4>	38	

* Following the change in fiscal year-end, FY2007 results for DSE, Olmetec / Olmetec Plus, Mevalotin and Evista are fifteen-months totals from Jan-07 to Mar-08.

Three months results from Jan-07 to Mar-07 are ¥14.1 billion (€89 million), ¥6.4 billion (€40 million), ¥1.6 billion (€10 million), and ¥1.0 billion (€6 million), respectively.

7-6. Asia / Latin America (ASCA)

1) Net Sales by Companies

	FY2008 Results				(Billion of yen)			
					FY2008 Forecast			
	1Q	Progress	YoY Changes		1st half	Full Year		
ASCA Total	<-10.5>	5.2	47.7%	0.5	<-10.8>	<-9.5>	11.0	23.0
Daiichi Pharmaceutical (Beijing) Co., Ltd. (DPP)	<10.9>	1.0	47.3%	0.1	<10.2>	<-1.5>	2.1	4.0
Shanghai Sankyo Pharmaceuticals Co., Ltd. (SSP)	<29.5>	0.7	40.9%	0.1	<56.9>	<62.6>	1.8	3.7
Daiichi Sankyo Korea Co., Ltd. (DSKR)	<4.3>	0.9	59.3%	0.0	<-13.8>	<-11.9>	1.5	3.0
Daiichi Sankyo (Thailand) Ltd. (DSTH)	<-4.9>	0.2	42.5%	0.0	<4.2>	<-4.1>	0.4	0.8
Daiichi Sankyo Taiwan Ltd. (DSTW)	<1.6>	0.9	48.3%	0.0	<4.4>	<5.9>	2.0	3.9
Daiichi Sankyo Brasil Farmacêutica Ltda. (DSBR)	<11.5>	1.0	44.2%	0.1	<18.4>	<13.7>	2.3	5.0
Daiichi Sankyo Venezuela, S.A. (DSVE)	<21.7>	0.5	51.4%	0.1	<3.0>	<2.1>	1.0	2.4

2) Sales of Major Products

	FY2008 Results				(Billion of yen)			
					FY2008 Forecast			
	1Q	Progress	YoY Changes		1st half	Full Year		
Olmesartan	<69.3>	1.3	51.3%	0.5	<50.0>	<42.5>	2.5	6.0
Levofloxacin	<-1.8>	1.9	48.1%	0.0	<3.0>	<2.2>	4.0	8.0
Pravastatin	<-3.1>	0.8	50.8%	0.0	<-6.6>	<-6.2>	1.5	3.0

8. Number of Employees

	FY2007		FY2008	
	Mar-08	MRs	Jun-08 *	MRs
<Japan>				
Daiichi Sankyo Co., Ltd. (DS)	5,925	2,400	6,024	2,400
Daiichi Sankyo Healthcare Co., Ltd. (DSHC)	396	150	399	150
<US>				
Daiichi Sankyo, Inc. (DSI)	2,446	1,550	2,667	1,590
Luitpold Pharmaceuticals, Inc. (LPI)	498	90	495	90
<Europe>				
Daiichi Sankyo Europe GmbH (DSE)	1,776	830	1,774	850
<Asia / Latin America>				
Daiichi Pharmaceutical (Beijing) Co., Ltd. (DPP)	443	143	443	143
Shanghai Sankyo Pharmaceuticals Co., Ltd. (SSP)	456	196	476	196
Daiichi Sankyo Hong Kong Ltd. (DSHK)	7	-	7	-
Daiichi Sankyo Korea Co., Ltd. (DSKR)	89	51	89	49
Daiichi Sankyo (Thailand) Ltd. (DSTH)	46	18	43	17
Daiichi Sankyo Taiwan Ltd. (DSTW)	150	65	158	65
Daiichi Sankyo Brasil Farmacéutica Ltda. (DSBR)	266	118	266	118
Daiichi Sankyo Venezuela, S.A. (DSVE)	123	70	123	70

* For overseas subsidiaries with different fiscal year-ends, figures as of Mar-08 are shown

Total number of Employees	15,349	15,731
Japan	9,048	9,106
Overseas	6,301	6,625

9. R&D Pipeline

Daiichi Sankyo Research & Development Pipeline (Development Stage)

Therapeutic Area	Main Existing Product	Phase1	Phase2
Cardiovascular diseases	Mevalotin Benicar/Olmetec Azor Welchol Olmetec Calblock Artist Mevalotin Kremezin Hanp Livalo Sunrythm Bepricor	DB-772d(US/EU) (oral factor Xa inhibitor) CS-8080(US/EU) (anti-arteriosclerosis)	DU-176b(US/EU/JP) (oral factor Xa inhibitor) ★CS-866CMB(JP) (Olmesartan/Hydrochlorothiazide combination) CS-747(JP) (Prasugrel/anti-platelet agent)
Glucose metabolic disorders	Welchol Fastic	AJD101(US/EU) (activation of the insulin signaling pathway)	CS-011(JP) (Rivoglitazone/ glitazone agent that improves insulin resistance) AJD101(JP) (activation of the insulin signaling pathway)
Infectious diseases	Levaquin / Tavanic Banan Cravit	CS-8958(US/EU) (anti-influenza/co-development with Biota)	CS-8958(JP) (anti-influenza)
Cancer	Topotecin Krestin	CS-7017(US) (PPAR γ activator) DE-766(JP) (Nimotuzumab/anti-EGFR antibody) <u>U3-1287(US)</u> (anti-HER3 antibody)	CS-1008(US) (anti-DR5 antibody)
Immunological allergic diseases	Zyrtec	CS-0777(US/EU) (immunomodulator) SUN13834(US) (Chymase inhibitor)	
Bone/Joint diseases	Loxonin Mobic		
Others	Venofer Evoxac Omnipaque Omniscan Feron Urief		SUN11031(JP) (Human ghrelin/anorexia nervosa) SUN11031(US/EU) (Human ghrelin/cachexia)

★additional indications, new formulations etc.

Change from the announcement of May 2008

New(underline)

: U3-1287 (US)

Change of Stage etc.

: AMG 162(JP, osteoporosis), SUN 0588r(JP)

Sales tie-up, License activity etc.

		Phase1	Phase2
—	—	HGF DNA therapy(US/EU) (coronary arterial diseases/sales agreement) SUN N8075(US/EU) (neuroprotectant/licensed-out to Cecoura)	HGF DNA therapy(US/EU) (peripheral arterial diseases/sales agreement) SUN N4057(US/EU)(Serotonin 1A receptor agonist) CS-088(US/EU/JP) (antiglaucoma/co-development with Santen)

Phase3	Application
<p>★CS-866DM(JP) (Olmesartan Medoxomil/diabetic nephropathy)</p> <p>★CS-866AZ(JP) (Olmesartan Medoxomil/Azelnidipine combination)</p> <p>★CS-8635(US) (Olmesartan Medoxomil/Amlodipine Besilate/Hydrochlorothiazide combination)</p>	<p>CS-747(US/EU) (Prasugrel/anti-platelet agent)</p> <p>★CS-8663(EU) (Olmesartan Medoxomil/Amlodipine Besilate combination)</p>
<p>CS-011(US/EU) (Rivoglitazone/ glitazone agent that improves insulin resistance)</p>	
<p>★levofloxacin inj(JP) (new quinolone)</p>	<p>★levofloxacin high-dose(JP) (new quinolone)</p>
<p>AMG 162(JP) (Denosumab/ anti-RANKL antibody/ P3; bone metastases of cancer, P3; osteoporosis)</p> <p>★CS-600G(JP) (Loxoprofen/gel)</p>	
<p>SUN Y7017(JP) (Memantine Hydrochloride/ mild to moderate and severe dementia of Alzheimer type)</p> <p>KMD-3213(China) (Silodosin/treatment of dysuria associated with benign prostatic hyperplasia)</p>	<p>★DL-8234(JP) (FERON add indic./hepatitis C/with Ribavirin)</p> <p>★SUN 0588r(JP) (Biopten add indic./BH4 responsive hyperphenylalaninemia /approval)</p>

Phase3	Application
<p>SUN A0026(North America) (Faropenem medoxomil/penem-type antibiotic /licensed-out to Replidyne)</p>	<p>DF-098(JP)(ActHIB/approval) HGF DNA therapy(JP) (Collatogene/peripheral arterial diseases/sales agreement) SUN 0588r(EU)(Sapropterin Hydrochloride/ hyperphenylalaninemia/licensed-out to BioMarin)</p>

* SUN A0026(North America): discontinuation following the termination of license agreement

<Historical Data>

1. Summary of Income Statement

(Billion of yen)

	FY2007								FY2008							
	1Q	2Q	2Q YTD	3Q	3Q YTD	4Q	Full Year	1Q								
Net sales	<-12.9> 100.0	<-3.3> 235.5	<-8.7> 100.0	<-3.0> 443.7	<-4.8> 100.0	<-7.3> 252.1	<-5.3> 100.0	184.3	<-5.3> 880.1	<-13.5> 100.0	203.7					
Cost of sales	24.6	57.9	26.6	55.3	25.5	113.2	27.2	68.5	26.1	181.7	28.7	52.8	26.7	234.6	23.9	48.6
Selling, general and administrative expenses	46.6	109.9	60.9	126.7	53.3	236.6	47.9	120.7	51.4	357.3	71.3	131.4	55.5	488.7	56.5	115.1
Research and development expenses	13.9	32.7	21.9	45.5	17.6	78.3	15.4	38.8	16.8	117.0	25.2	46.5	18.6	163.5	18.1	36.9
Other expenses	32.7	77.1	39.0	81.2	35.7	158.3	32.5	82.0	34.5	240.3	46.1	84.9	37.0	325.2	38.4	78.2
Operating income	<11.6> 28.8	<48.5> 67.8	<19.9> 12.5	<17.2> 26.1	<18.8> 21.2	<98.8> 93.9	<15.0> 24.9	<1.0> 62.9	<1.0> 22.5	<15.8> 156.8	<0.0> 0.0	<17.8> 0.1	<156.8> 17.8	<41.0> 19.6	<40.0> 40.0	
Non-operating income		5.9		2.8		8.7		3.5		12.2		4.8		17.0		3.6
Non-operating expenses		2.1		-0.2		1.9		1.0		2.9		1.9		4.8		2.8
Ordinary income	<5.6> 30.4	<42.6> 71.7	<14.2> 14.0	<12.8> 29.0	<13.6> 22.7	<65.4> 100.7	<23.9> 25.9	<166.0> 65.4	<49.5> 23.9	<1.6> 166.0	<3.0> 1.6	<19.2> 3.0	<169.1> 19.2	<43.0> 20.1	<40.9> 40.9	
Extraordinary gains		3.9		0.1		4.0		0.1		4.1		12.0		16.1		0.0
Extraordinary losses		4.0		2.6		6.7		2.3		9.0		9.4		18.3		1.3
Income before income taxes and minority interests	30.4	71.5	12.7	26.5	22.1	98.0	25.1	63.2	23.2	161.2	3.1	5.7	19.0	166.9	19.4	39.5
Net income	<-13.7> 17.6	<-0.3> 41.4	<-9.9> 9.0	<234.8> 18.8	<24.1> 13.6	<96.2> 60.2	<14.3> 14.3	<36.2> 36.2	<24.1> 13.9	<96.4> 96.4	<0.7> 0.7	<1.2> 1.2	<11.1> 11.1	<97.7> 97.7	<39.4> 12.3	<25.1> 25.1

<Performance excluding the effects of changes in fiscal year-end of the U.S./European subsidiaries and non-pharmaceutical business>

(Billion of yen)

	FY2007								FY2008							
	1Q	2Q	2Q YTD	3Q	3Q YTD	4Q	Full Year	1Q								
Net sales	<2.5> 100.0	<6.5> 213.3	<4.4> 100.0	<7.7> 413.2	<5.6> 100.0	<3.2> 243.1	<5.1> 100.0	<834.0> 656.3	<100.0> 100.0	<177.7> 177.7	<834.0> 834.0	<100.0> 100.0	<203.7> 203.7			
Cost of sales	22.1	47.2	23.9	47.8	23.0	95.0	24.9	60.5	23.7	155.5	26.8	47.6	24.3	203.0	23.9	48.6
Selling, general and administrative expenses	46.9	100.0	62.8	125.5	54.6	225.5	49.2	119.6	52.6	345.1	73.6	130.8	57.1	475.8	56.5	115.1
Research and development expenses	15.1	32.2	22.7	45.3	18.7	77.5	15.9	38.5	17.7	116.0	26.1	46.4	19.5	162.4	18.1	36.9
Other expenses	31.8	67.8	40.1	80.2	35.8	148.0	33.3	81.1	34.9	229.1	47.5	84.4	37.6	313.5	38.4	78.2
Operating income	<34.2> 31.0	<69.3> 66.2	<42.7> 13.3	<19.8> 26.6	<32.5> 22.4	<155.8> 92.7	<0.4> 25.9	<-0.7> 63.0	<29.2> 23.7	<155.8> 155.8	<-0.4> -0.4	<-0.7> -0.7	<18.6> 18.6	<155.1> 155.1	<19.6> 19.6	<40.0> 40.0
Non-operating income		5.6		2.8		8.4		3.5		11.9		4.8		16.6		3.6
Non-operating expenses		2.1		-0.2		1.9		1.0		2.9		1.8		4.7		2.8
Ordinary income	<27.6> 32.7	<58.4> 69.7	<35.4> 14.8	<15.4> 29.5	<26.7> 24.0	<164.8> 99.2	<1.3> 27.0	<2.3> 65.5	<24.2> 25.1	<7.9> 164.8	<5.0> 1.3	<7.4> 2.3	<167.1> 20.0	<41.4> 20.1	<40.9> 40.9	
Extraordinary gains		2.2		0.1		2.3		0.1		2.4		5.0		7.4		0.0
Extraordinary losses		4.0		2.6		6.6		2.3		8.9		7.9		16.9		1.3
Income before income taxes and minority interests	31.8	67.9	13.5	27.0	23.0	94.9	26.1	63.4	24.1	158.3	-0.4	-0.7	18.9	157.6	19.4	39.5
Net income	<23.3> 17.9	<28.4> 38.1	<25.0> 9.6	<> 19.2	<132.9> 13.9	<96.0> 57.3	<-0.5> 15.9	<-0.9> 38.7	<11.4> 14.6	<95.1> 96.0	<-0.5> -0.5	<-0.9> -0.9	<11.4> 11.4	<95.1> 95.1	<34.2> 12.3	<25.1> 25.1

2. Sales of Global Products

(Billion of yen)

	FY2007								FY2008	
	1Q	2Q	2Q YTD	3Q	3Q YTD	4Q	Full Year	1Q		
Olmesartan	<3.6> 53.1	<33.1> 43.6	<15.1> 96.6	<35.8> 54.0	<21.8> 150.7	<22.8> 44.9	<22.0> 195.6	<-4.5> 50.7		
Olmotec (JPN)	<40.5> 13.8	<31.4> 12.6	<36.0> 26.4	<29.5> 17.6	<33.3> 44.0	<21.4> 11.2	<30.7> 55.2	<12.8> 15.6		
Benicar / Benicar HCT (US)	<-36.1> 22.8	<23.0> 21.7	<-16.5> 44.5	<22.0> 24.1	<-6.1> 68.6	<-2.0> 19.3	<-5.3> 87.9	<2.6> 23.4		
Azor (US)	-	-	-	1.9	1.9	0.7	2.5	<> 1.4		
Olmotec / Olmotec Plus* (EU)	<185.4> 14.9	<52.4> 7.4	<121.6> 22.3	<45.0> 8.3	<93.8> 30.6	<66.5> 11.2	<85.6> 41.8	<-44.3> 8.3		
Export / Asian & LA subsidiaries, etc.	<196.1> 1.6	<184.6> 1.9	<189.6> 3.5	<199.0> 2.1	<193.1> 5.6	<180.7> 2.5	<189.2> 8.1	<30.4> 2.0		
Levofloxacin	<18.0> 29.5	<-2.0> 23.5	<8.0> 52.9	<-1.0> 32.1	<5.0> 85.1	<4.0> 23.7	<4.0> 108.7	<-13.0> 25.8		
Cravit (JPN)	<3.5> 12.1	<7.2> 10.0	<5.1> 22.1	<-8.5> 15.5	<-1.0> 37.6	<11.5> 9.8	<1.4> 47.4	<-15.5> 10.2		
Export, etc.	<41.1> 10.8	<20.0> 6.9	<8.6> 17.7	<13.2> 9.7	<10.2> 27.4	<-5.5> 6.6	<-6.8> 34.0	<-11.3> 9.6		
Royalty	<8.5> 4.7	<8.6> 4.6	<8.6> 9.3	<-6.9> 4.8	<2.7> 14.1	<3.0> 5.4	<-2.8> 19.5	<-12.6> 4.1		
Asian subsidiaries	<39.6> 2.0	<20.7> 1.9	<29.5> 3.9	<19.6> 2.1	<25.9> 6.0	<2.9> 1.9	<19.5> 7.8	<-1.8> 1.9		
Pravastatin	<16.2> 21.7	<28.6> 18.6	<22.4> 40.3	<-12.3> 21.6	<-19.2> 61.9	<-14.1> 14.5	<-18.3> 76.5	<-25.8> 16.1		
Mevalotin (JPN)	<-8.4> 16.3	<-9.6> 15.4	<-9.0> 31.7	<-8.7> 18.2	<-8.9> 49.9	<-10.3> 11.6	<-9.1> 61.6	<-17.1> 13.5		
Export	<72.5> 1.7	<-83.7> 1.2	<-78.5> 2.9	<-54.7> 1.4	<-74.1> 4.3	<-68.2> 0.7	<-73.4> 5.0	<-39.0> 1.0		
European subsidiaries*	<77.9> 2.8	<22.8> 1.3	<26.4> 4.1	<-13.3> 1.2	<-14.4> 5.4	<1.5> 1.3	<-11.5> 6.7	<-74.3> 0.7		
Asian & LA subsidiaries	<270.7> 0.8	<210.4> 0.8	<237.2> 1.6	<224.0> 0.8	<232.8> 2.4	<212.7> 0.8	<227.5> 3.2	<-3.1> 0.8		

* The accounting period of Daiichi Sankyo Europe GmbH (DSE) was 15 months from January 2007 to March 2008, following a change in its fiscal year-end from December to March. Three months results of Olmotec / Olmotec Plus and Pravastatin from Jan-07 to Mar-07 were ¥6.4 billion (€40 million) and ¥1.6 billion (€10 million), respectively.

4. Overseas Sales

(Billion of yen)

	FY2007							FY2008	
	1Q	2Q	2Q YTD	3Q	3Q YTD	4Q	Full Year	1Q	
Overseas sales	<-8.4>	<-4.4>	<-3.2>	<-14.2>	<-1.9>	<-4.2>	<-0.5>	<-15.9>	88.7
Overseas sales ratio	105.5	83.0	188.5	92.4	280.9	77.8	358.6	43.5%	88.7
North America	<-30.0>	<0.5>	<-17.6>	<-15.0>	<-8.3>	<-11.9>	<-9.1>	<-3.9>	58.3
Europe*	<-41.8>	<-3.7>	<-27.3>	<-2.0>	<-19.7>	<-7.7>	<-16.8>	<-42.6>	22.4
Asia / Latin America, etc	<-39.2>	<-33.2>	<-36.1>	<-38.3>	<-36.9>	<-17.0>	<-31.9>	<-22.3>	8.0

* The accounting period of Daiichi Sankyo Europe GmbH (DSE) was 15 months from January 2007 to March 2008, following a change in its fiscal year-end from December to March.
The net sales of DSE for the period from January to March 2007 was ¥14.1 billion.

5. Consolidated Segment information - Operating Segment

(Billion of yen)

	FY2007							FY2008	
	1Q	2Q	2Q YTD	3Q	3Q YTD	4Q	Full Year	1Q	
Net Sales	<-12.9>	<-3.3>	<-8.7>	<-3.0>	<-4.8>	<-7.3>	<-5.3>	<-13.5>	203.7
Pharmaceuticals	<-8.8>	<2.2>	<-3.9>	<7.0>	<-0.2>	<3.1>	<0.4>	<-10.2>	202.9
Domestic	<-3.9>	<4.0>	<-0.3>	<2.3>	<-0.7>	<1.8>	<-0.9>	<-8.2>	103.3
Overseas*	<-6.5>	<-8.9>	<-0.3>	<16.2>	<4.6>	<3.2>	<4.3>	<-14.1>	88.7
OTC drugs	<-11.5>	<-8.5>	<-0.6>	<-0.1>	<-0.4>	<-30.6>	<4.9>	<-3.1>	10.2
Other	<-57.9>	<-53.5>	<-55.7>	<-43.4>	<-52.0>	<-69.6>	<-57.4>	<-91.5>	0.8
Operating income	<-11.6>	<-48.5>	<-19.9>	<-17.2>	<-18.8>	<-98.8>	<-15.0>	<-41.0>	40.0
Pharmaceuticals	<-15.1>	<-56.5>	<-24.1>	<-18.4>	<-21.7>	<-140.5>	<-18.5>	<-42.3>	39.4
Other	<>	<>	<>	<>	<>	<>	<>	<>	0.5

* The accounting period of Daiichi Sankyo Europe GmbH (DSE) was 15 months from January 2007 to March 2008, following a change in its fiscal year-end from December to March.
The operating results of DSE for the period from January to March 2007 was net sales of ¥14.1 billion and operating income of ¥1.8 billion.

6. Consolidated Segment information - Geographic Segment

(Billion of yen)

	FY2007							FY2008	
	1Q	2Q	2Q YTD	3Q	3Q YTD	4Q	Full Year	1Q	
Net Sales	<-12.9>	<-3.3>	<-8.7>	<-3.0>	<-4.8>	<-7.3>	<-5.3>	<-13.5>	203.7
Japan	<-15.3>	<-11.8>	<-13.6>	<-4.1>	<-10.3>	<-11.1>	<-10.4>	<-12.6>	132.7
North America	<-36.6>	<-19.1>	<-17.4>	<-24.7>	<-5.8>	<-11.4>	<-7.1>	<-12.5>	50.7
Europe*	<98.3>	<18.2>	<66.0>	<21.6>	<52.5>	<28.2>	<46.1>	<-53.1>	15.2
Asia / Latin America, etc	<59.1>	<73.8>	<66.5>	<52.7>	<61.5>	<36.3>	<55.0>	<-16.9>	5.2
Operating income	<-11.6>	<-48.5>	<-19.9>	<-17.2>	<-18.8>	<-98.8>	<-15.0>	<-41.0>	40.0
Japan	47.4	21.9	69.4	47.3	116.7	-9.5	107.1	18.5	
North America	13.2	9.2	22.5	12.5	35.0	2.6	37.6	16.9	
Europe*	4.4	-1.1	3.4	1.4	4.8	5.9	10.7	1.2	
Asia / Latin America, etc	0.7	0.5	1.3	0.7	2.0	0.4	2.5	0.7	

* The accounting period of Daiichi Sankyo Europe GmbH (DSE) was 15 months from January 2007 to March 2008, following a change in its fiscal year-end from December to March.
The operating results of DSE for the period from January to March 2007 was net sales of ¥14.1 billion and operating income of ¥1.8 billion.

7. Status of Major Companies

7-1. Daiichi Sankyo Co., Ltd.

(Billion of yen)

	FY2007							FY2008	
	1Q	2Q	2Q YTD	3Q	3Q YTD	4Q	Full Year	1Q	
Total net sales of ethical pharmaceuticals	<0.1>	<5.0>	<2.4>	<-0.7>	<1.2>	<3.5>	<1.6>	<-8.8>	100.9
Cardiovascular disease	63.8	58.5	122.3	71.8	194.1	48.4	242.5	<-5.9>	60.0
Olmotec <antihypertensive>	<40.5>	<31.4>	<36.0>	<29.5>	<33.3>	<21.4>	<30.7>	<12.8>	15.6
Calblock <antihypertensive>	<17.8>	<16.6>	<17.2>	<10.2>	<14.4>	<23.1>	<16.3>	<19.4>	3.0
Artist <antihypertensive>	<5.2>	<16.3>	<10.2>	<3.7>	<7.8>	<16.5>	<9.6>	<3.3>	5.7
Mevalotin <antihyperlipidemic agent>	<-8.4>	<-9.6>	<-9.0>	<-8.7>	<-8.9>	<-10.3>	<-9.1>	<-17.1>	13.5
Kremezin <treatment for chronic renal failure>	<4.2>	<7.9>	<1.6>	<1.8>	<1.7>	<1.8>	<1.7>	<3.9>	3.2
Hanp <treatment for acute cardiac failure>	<4.2>	<13.0>	<7.8>	<-1.7>	<3.8>	<15.5>	<6.4>	<-7.8>	2.4
Livalo <antihyperlipidemic agent>	<5.9>	<7.5>	<6.7>	<3.0>	<5.3>	<10.1>	<6.3>	<10.0>	1.5
Sunrhythm <antiarrhythmic agent>	<-0.6>	<10.6>	<4.5>	<-2.4>	<1.9>	<7.5>	<3.0>	<-4.2>	3.1
Fastic <antidiabetic agent>	<-8.1>	<2.9>	<-3.0>	<-5.6>	<-3.9>	<-4.0>	<-4.0>	<-0.5>	1.3
Infectious diseases / bone and joint diseases / immunological allergic diseases / urology	33.6	30.6	64.2	45.9	110.1	27.8	137.9	<-8.3>	30.8
Cravit <synthetic antibacterial agent>	<3.5>	<7.2>	<5.1>	<-8.5>	<-1.0>	<11.5>	<1.4>	<-15.5>	10.2
Loxonin <anti-inflammatory analgesic>	<4.0>	<16.2>	<9.7>	<9.0>	<9.4>	<6.0>	<8.7>	<2.2>	8.4
Mobic <anti-inflammatory analgesic>	<-3.5>	<3.1>	<-0.5>	<-10.6>	<-4.2>	<-2.8>	<-4.0>	<-13.1>	2.4
Urief <treatment for dysuria>	<36.2>	<401.8>	<120.9>	<145.4>	<130.7>	<168.5>	<139.3>	<59.7>	1.8
Zyrtec <antiallergic agent>	<-8.9>	<-13.8>	<-11.0>	<-18.4>	<-13.9>	<-0.6>	<-9.5>	<-23.8>	2.0
Contrast agents / cancer / gastric diseases	15.8	14.5	30.3	17.1	47.4	11.3	58.6	<-6.4>	12.3
Omnipaque <contrast agent>	<-3.0>	<-2.4>	<-2.7>	<-6.3>	<-4.0>	<12.7>	<-1.2>	<-11.3>	7.3
Topotecin <anticancer agent>	<15.1>	<20.9>	<17.8>	<4.0>	<12.4>	<18.8>	<13.8>	<0.7>	1.6

7-2. Daiichi Sankyo Healthcare Co., Ltd

(Billion of yen)

	FY2007							FY2008	
	1Q	2Q	2Q YTD	3Q	3Q YTD	4Q	Full Year	1Q	
Daiichi Sankyo Healthcare Co., Ltd	<-11.5>	<8.5>	<-0.6>	<0.1>	<-0.4>	<30.6>	<4.9>	<-3.1>	10.2
LuLu Series	<-11.7>	<-8.7>	<-9.5>	<3.4>	<-4.3>	<28.9>	<-0.5>	<8.7>	1.2
Gaster 10	<-9.8>	<13.0>	<0.2>	<-28.9>	<-13.1>	<64.0>	<-3.0>	<-15.5>	0.7
Shin-Sankyo Ichoyaku series	<-9.8>	<-5.5>	<-7.6>	<39.1>	<10.9>	<45.4>	<17.5>	<7.9>	0.7
Patecs series	<60.0>	<63.1>	<61.4>	<41.1>	<55.3>	<63.6>	<56.6>	<-19.5>	0.8
Transino	-	<->	<->	<->	<->	<->	<->	<->	0.7

7-3. Daiichi Sankyo, Inc. (US)

(Billion of yen)

	FY2007								FY2008	
	1Q	2Q	2Q YTD	3Q	3Q YTD	4Q	Full Year	1Q		
Daiichi Sankyo, Inc. (DSI)	<-29.8>	<-21.1>	<-11.6>	<-35.1>	<-1.3>	<-16.6>	<-2.7>	<-12.0>		
mil USD	33.2	31.9	65.1	37.6	102.7	24.2	126.9	37.2		
	<-32.7>	<-19.4>	<-14.1>	<-39.6>	<-0.5>	<-3.6>	<-0.4>	<-29.4>		
mil USD	275	271	546	330	876	234	1,110	356		
Benicar / Benicar HCT <antihypertensive>	<-36.1>	<-23.0>	<-16.5>	<-22.0>	<-6.1>	<-2.0>	<-5.3>	<2.6>		
mil USD	22.8	21.7	44.5	24.1	68.6	19.3	87.9	23.4		
	<-38.8>	<-21.3>	<-18.9>	<-26.3>	<-6.8>	<-11.6>	<-3.0>	<18.6>		
mil USD	188	184	373	212	585	184	769	223		
Azor <antihypertensive>	-	-	-	-	1.9	1.9	0.7	<->		
mil USD	-	-	-	16	16	6	22	<->		
	<->	<->	<->	<->	<->	<->	<->	<->		
Welchol <antihyperlipidemic / type 2 diabetes>	<-36.6>	<-27.8>	<-13.1>	<-29.5>	<-1.7>	<-3.4>	<-2.1>	<11.0>		
mil USD	5.8	5.6	11.4	6.2	17.6	5.1	22.7	6.4		
	<-36.4>	<-26.0>	<-15.6>	<-34.1>	<-2.4>	<-9.6>	<-0.2>	<-28.2>		
mil USD	48	48	96	55	150	49	199	62		

7-4. Luitpold Pharmaceuticals, Inc. (US)

(Billion of yen)

	FY2007								FY2008	
	1Q	2Q	2Q YTD	3Q	3Q YTD	4Q	Full Year	1Q		
Luitpold Pharmaceuticals, Inc. (LPI)	<-50.2>	<-14.3>	<-29.6>	<-2.3>	<-20.9>	<-0.6>	<-16.3>	<-13.8>		
mil USD	11.9	12.7	24.6	13.5	38.1	13.0	51.1	13.5		
	<-52.2>	<-12.6>	<-31.6>	<-5.9>	<-21.5>	<-12.9>	<-14.3>	<-31.4>		
mil USD	98	108	206	119	325	122	447	129		
Venofer <treatment for iron deficiency anemia>	<-50.8>	<-16.5>	<-28.4>	<-3.5>	<-21.1>	<-5.5>	<-17.6>	<-23.1>		
mil USD	6.8	8.0	14.8	8.2	23.0	8.1	31.1	8.3		
	<-52.8>	<-14.6>	<-30.4>	<-0.3>	<-21.7>	<-5.7>	<-15.6>	<-42.2>		
mil USD	56	68	124	72	196	76	272	80		

7-5. Daiichi Sankyo Europe GmbH

(Billion of yen)

	FY2007								FY2008	
	1Q	2Q	2Q YTD	3Q	3Q YTD	4Q	Full Year	1Q		
Daiichi Sankyo Europe GmbH (DSE)	<-103.6>	<-22.5>	<-71.1>	<-26.3>	<-57.6>	<-32.8>	<-51.0>	<-53.1>		
mil €	32.3	13.0	45.3	14.5	59.8	18.2	78.0	15.2		
	<-79.4>	<-9.2>	<-51.8>	<-14.7>	<-40.9>	<-27.4>	<-37.5>	<-54.2>		
mil €	203	80	283	88	371	115	486	93		
Olmotec / Olmetec Plus <antihypertensive>	<-185.4>	<-52.4>	<-121.6>	<-45.0>	<-93.8>	<-66.5>	<-85.6>	<-44.3>		
mil €	14.9	7.4	22.3	8.3	30.6	11.2	41.8	8.3		
	<-151.5>	<-35.5>	<-96.5>	<-31.0>	<-73.4>	<-58.4>	<-69.0>	<-45.6>		
mil €	94	45	139	51	190	71	261	51		
Mevalotin <antihyperlipidemic agent>	<-77.9>	<-22.8>	<-26.4>	<-13.3>	<-14.4>	<-1.5>	<-11.5>	<-74.3>		
mil €	2.8	1.3	4.1	1.2	5.4	1.3	6.7	0.7		
	<-56.8>	<-31.5>	<-12.1>	<-21.4>	<-2.3>	<-1.2>	<-1.5>	<-74.9>		
mil €	18	8	26	7	33	8	42	4		
Evista <osteoporosis>	<->	<-38.1>	<-134.7>	<-62.6>	<-104.3>	<-51.5>	<-87.1>	<-71.7>		
mil €	1.9	0.7	2.6	1.3	3.9	1.4	5.2	3.2		
	<->	<-45.8>	<-108.1>	<-46.6>	<-82.7>	<-43.6>	<-70.4>	<-67.7>		
mil €	12	4	16	8	24	9	33	20		

* Following the change in fiscal year-end, FY2007 results for DSE, Olmetec / Olmetec Plus, Mevalotin and Evista are fifteen-months totals from Jan-07 to Mar-08.

Three months results from Jan-07 to Mar-07 were ¥14.1 billion (€89 million), ¥6.4 billion (€40 million), ¥1.6 billion (€10 million), and ¥1.0 billion (€6 million), respectively.

7-6. Asia / Latin America (ASCA)

1) Net Sales by Companies

(Billion of yen)

	FY2007								FY2008	
	1Q	2Q	2Q YTD	3Q	3Q YTD	4Q	Full Year	1Q		
ASCA Total	4.7	5.2	9.9	5.2	15.1	5.9	21.0	<-10.5>		
Daiichi Pharmaceutical (Beijing) Co., Ltd. (DPP)	0.9	1.0	1.9	1.0	2.9	1.2	4.1	<10.9>		
Shanghai Sankyo Pharmaceuticals Co., Ltd. (SSP)	0.6	0.6	1.1	0.7	1.8	0.5	2.3	<-29.5>		
Daiichi Sankyo Korea Co., Ltd. (DSKR)	0.9	0.9	1.7	0.9	2.6	0.8	3.4	<4.3>		
Daiichi Sankyo (Thailand) Ltd. (DSTH)	0.2	0.2	0.4	0.2	0.6	0.2	0.8	<-4.9>		
Daiichi Sankyo Taiwan Ltd. (DSTW)	0.9	0.9	1.9	0.9	2.8	0.9	3.7	<1.6>		
Daiichi Sankyo Brasil Farmacêutica Ltda. (DSBR)	0.9	1.0	1.9	1.0	3.0	1.4	4.4	<-11.5>		
Daiichi Sankyo Venezuela, S.A. (DSVE)	0.4	0.5	1.0	0.5	1.5	0.9	2.4	<-21.7>		

2) Sales of Major Products

(Billion of yen)

	FY2007								FY2008	
	1Q	2Q	2Q YTD	3Q	3Q YTD	4Q	Full Year	1Q		
Olmesartan	0.8	0.9	1.7	1.0	2.7	1.5	4.2	<-69.3>		
Levofloxacin	2.0	1.9	3.9	2.1	6.0	1.9	7.8	<-1.8>		
Pravastatin	0.8	0.8	1.6	0.8	2.4	0.8	3.2	<-3.1>		



Numerical values for future projections in this material are derived from our judgments and assumptions based on the currently available information and they include risks and uncertainty. For this reason, the actual results may differ from the projected numerical values.